Chinese instructions for Sotorasib

1. Indications:

Sotoracib is mainly indicated for patients with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutations. The drug is a targeted therapy designed to combat this specific genetic mutation, providing a new treatment option for eligible patients.

2. Mechanism of action:

Sotoracib is a KRAS G12C inhibitor that blocks the growth signaling pathway of cancer cells by specifically interfering with the G12C mutation of the KRAS gene. It binds to the KRAS G12C protein in tumor cells and inhibits its activity, thereby slowing down or preventing the proliferation of tumor cells and promoting tumor apoptosis.

3. Pharmacology:

Sotorasiib shows high selectivity in vivo, mainly acting on KRAS G12C mutated cancer cells, while having relatively little effect on normal cells. It regulates cell growth and differentiation by interfering with intracellular signaling pathways, thereby combating the development of tumors. Pharmacological studies have shown that sotoraxib has good tissue distribution and can quickly reach therapeutic concentrations, which provides a basis for its clinical application.

4. Dosage and usage:

Patients should consult their doctor before using sotorasibu and use it correctly in accordance with their doctor's recommendations. It is generally recommended to take it orally once a day. Specific adjustments in dosage will be based on the patient's condition, physical condition, and physician recommendations. During the medication period, patients must take it on time and do not change the dosage or interrupt treatment at will.

5. Side effects:

Sotorasiib may cause some side effects, including but not limited to: fatigue, loss of appetite, nausea, vomiting, rash, dizziness, etc. Some patients may experience more serious side effects, such as difficulty breathing, abnormal liver function, etc. If any discomfort occurs during use, the patient should promptly inform the doctor for further evaluation and treatment.

6. Warnings and precautions:

Patients should pay attention to the following while using sotorasiib:

1.Regular medical monitoring, including hematology tests, liver function tests, etc.

2.Pay attention to the correct usage of medicines and do not overuse or interrupt treatment.

3.Pregnant women, lactating women and those planning pregnancy should inform their doctor before use.

4.During medication, it is necessary to avoid drinking alcohol and certain drug interactions to avoid aggravating adverse reactions.

7. Contraindications:

Sotoraxib is contraindicated in patients who are allergic to the drug ingredients. Before use, doctors need to understand the patient's allergy history and drug usage in detail to ensure safe use by the patient.

8. Drug interactions:

Patients need to inform their doctor about all medications they are taking while taking sotoraxib, including prescription drugs, over-the-counter drugs, and supplements. Some medications may interact with sotoraxib, affecting its efficacy or increasing the occurrence of side effects.

9. Medication for special groups:

For elderly patients, patients with abnormal liver function, and patients with abnormal renal function, doctors may need to adjust the dosage or monitoring frequency to ensure the safe use of the drug. Pregnant women, lactating women and those planning pregnancy should consider carefully before use and use it under the guidance of a doctor.

10. Listing and price situation:

The original drug of sotorasibu has not yet been launched in China, so patients cannot purchase it domestically and need to purchase sotorasibu through overseas channels. The price of the original version of sotorasibu in Hong Kong, China, with the specifications of 120mg*240 tablets, is around 8 million, and the price of the European version of the original drug with the same specifications is around 4 million, which is relatively expensive. The cheaper ones are the generic drugs marketed abroad. For example, the price of generic drugs in Laos and Bangladesh is around two to three thousand yuan. The price is relatively cheap, and the ingredients of foreign generic drugs are basically the same as the original drugs.

In summary, sotorasiib is a new treatment drug for KRAS G12C mutated non-small cell lung cancer. Its unique mechanism of action and clinical effects bring new hope to relevant patients. However, during use, patients need to closely follow the doctor's advice and conduct regular monitoring to ensure the safe and effective use of the drug.